Plasminogen is the body's master clot-dissolving precursor. Secreted by the liver and distributed throughout the bloodstream and mucosal tissues, it is activated to plasmin¹¹ plasmin
the active serine protease that cleaves fibrin, dissolves clots, and clears debris from injured mucosal surfaces wherever the body needs to remodel or repair tissue. In the middle ear, this fibrinolytic activity is essential — infections naturally produce fibrin as part of the inflammatory response, and plasmin dissolves it before it accumulates into permanent, obstructive deposits.

The Lys38Glu variant (c.112A>G, historically called K19E before signal peptide corrections standardized numbering) swaps a positively charged lysine for a negatively charged glutamic acid at position 38 of the mature protein, located in the PAN/Apple domain. This is the most common disease-causing mutation in the PLG gene worldwide, found in 34% of alleles among documented plasminogen deficiency patients. The variant impairs the protein's secretion from liver cells — mutant plasminogen is retained and degraded rather than efficiently released into circulation — leaving mucosal surfaces chronically short of the fibrinolytic activity they need.

The Mechanism

When plasminogen levels fall sufficiently, fibrin cannot be cleared from inflamed mucosal surfaces at the rate it is deposited. The result is the accumulation of ligneous (woody) pseudomembranes²² ligneous (woody) pseudomembranes
thick, fibrin-rich masses that replace normal mucosal tissue with a wood-like material; "ligneous" derives from the Latin for wood, describing their texture. In the middle ear, uncleaned fibrin creates an ideal matrix for bacterial colonization and chronic infection. In mouse models, complete plasminogen deficiency causes 100% of animals to develop chronic otitis media³³ complete plasminogen deficiency causes 100% of animals to develop chronic otitis media
with bacterial colonization by five different species, extensive fibrin deposition, and neutrophil/macrophage infiltration — all within 18 weeks.

The Lys38Glu variant in humans is not a null allele — heterozygous carriers have residual plasminogen activity and mostly do not develop overt ligneous disease. The clinical spectrum runs from asymptomatic carriers (one functional copy is usually enough for adequate fibrinolysis) through increased susceptibility to recurrent otitis media, to severe ligneous conjunctivitis and other mucosal pseudomembranes in compound heterozygotes or homozygotes who carry two loss-of-function alleles.

The Evidence

The landmark clinical series by Tefs et al. in Blood (2006), covering 50 patients with confirmed type I plasminogen deficiency⁴⁴ Tefs et al. in Blood (2006), covering 50 patients with confirmed type I plasminogen deficiency
largest cohort study to date, across multiple countries, established Lys38Glu as the most prevalent disease allele worldwide (34% of pathogenic PLG alleles in the cohort). Otitis media was a documented manifestation in 14% of these patients — the fourth most common mucosal site after eyes (80%), gums (34%), and respiratory tract (16%).

At the population level, the 23andMe GWAS of over 200,000 Europeans identified the PLG locus as genome-wide significantly associated with childhood ear infection susceptibility⁵⁵ identified the PLG locus as genome-wide significantly associated with childhood ear infection susceptibility
OR=1.43, p<5×10⁻⁸, from the landmark 2017 Nature Communications GWAS of 23 common infections. An OR of 1.43 is unusually high for a common infection GWAS — most GWAS hits for infectious disease susceptibility show ORs in the 1.1–1.2 range — reflecting the direct mechanistic link between PLG function and middle ear fibrin clearance.

A targeted multi-omic study of 718 otitis-prone families identified the Lys38Glu variant in four multi-ethnic families showing an autosomal dominant pattern with reduced penetrance⁶⁶ identified the Lys38Glu variant in four multi-ethnic families showing an autosomal dominant pattern with reduced penetrance
Bootpetch et al., Scientific Reports 2020, reinforcing the biological plausibility even though the smaller family-based TDT did not reach statistical significance.

In the clinical setting, type I plasminogen deficiency is diagnosed in approximately 1.6 per million individuals⁷⁷ type I plasminogen deficiency is diagnosed in approximately 1.6 per million individuals
Shapiro & Nakar, Blood 2025, with the diagnosis frequently delayed because early presentations mimic common conditions — clinicians often attribute repeated ear infections to Eustachian tube dysfunction, adenoid hypertrophy, or daycare exposure before the underlying fibrinolytic defect is recognized.

Practical Implications

For carriers of a single Lys38Glu allele (AG genotype), the risk is a modest elevation in recurrent ear infection susceptibility, not overt plasminogen deficiency. One functional PLG copy is generally sufficient to maintain near-normal fibrinolysis; the association observed in the GWAS likely reflects heterozygous dosage effects on mucosal fibrin clearance during infections.

For those with two risk alleles (GG) or those who are compound heterozygotes (one Lys38Glu allele plus a different loss-of-function PLG allele not captured by this SNP), the clinical picture shifts significantly: plasminogen levels can fall to 5–17% of normal, and ligneous pseudomembranes can form across multiple mucosal surfaces simultaneously. The FDA approved an intravenous human plasma-derived plasminogen concentrate (Ryplazim) in 2021 — the first specific treatment for this condition.

Recurrent otitis media in a child with an ear infection history that seems disproportionate to typical risk factors — particularly if there are also eye, gum, or respiratory membrane abnormalities — warrants plasminogen level testing.

Interactions

The pathogenicity of Lys38Glu depends strongly on the status of the second PLG allele. Compound heterozygosity — carrying Lys38Glu on one chromosome and a different pathogenic PLG mutation (stop, frameshift, splice site, or other missense) on the other — produces much lower residual plasminogen activity than heterozygosity for Lys38Glu alone. Individuals in families with known plasminogen deficiency should consider comprehensive PLG sequencing rather than relying on this single rsid to characterize their risk.

No gene-gene interaction compound actions are proposed at this time, as the primary clinical modifier is the second PLG allele (not captured in a single-variant GWAS entry).

This variant, together with rs429358, determines your APOE genotype. The rs7412 variant causes a missense change at position 176 of the APOE protein, substituting arginine with cysteine (p.Arg176Cys). This defines the APOE ε2 isoform.

The Mechanism

The E2 isoform has reduced affinity for the LDL receptor compared to E3, which paradoxically leads to lower LDL cholesterol in most carriers. The arginine-to-cysteine substitution alters the protein's lipid-binding properties, generally leading to more efficient cholesterol clearance from the bloodstream.

The Evidence

The E2 allele is generally protective for cardiovascular health. E2 carriers typically have lower LDL cholesterol and better lipid profiles overall. A large neuropathological study¹¹ large neuropathological study
Reiman et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes. Nat Commun, 2020 of over 5,000 individuals confirmed that E2/E2 homozygotes have exceptionally low Alzheimer's risk — roughly 40% lower than E3/E3.

However, the rare E2/E2 genotype (~1% of the population) can sometimes be associated with type III hyperlipoproteinemia²² A rare lipid disorder (OMIM #617347) where cholesterol-rich remnant particles accumulate, causing yellowish skin deposits and elevated cardiovascular risk, particularly when combined with other metabolic triggers such as obesity, diabetes, or hypothyroidism.

Practical Implications

The E2 allele is generally protective for cardiovascular health and Alzheimer's disease. E2 carriers typically have lower LDL cholesterol and better lipid profiles overall. However, the rare E2/E2 genotype (~1% of the population) can sometimes be associated with type III hyperlipoproteinemia, particularly when combined with other metabolic triggers such as obesity, diabetes, or hypothyroidism.

Interactions

The rs7412 and rs429358 variants together determine your complete APOE genotype (E2/E2, E2/E3, E3/E3, E3/E4, E2/E4, or E4/E4), which has implications for both cardiovascular health and Alzheimer's risk.

Every heartbeat is a precisely timed surge of calcium flooding the cardiac muscle cell, binding to troponin C, and pulling troponin T¹¹ troponin T
Cardiac troponin T (encoded by TNNT2) is the tropomyosin-binding subunit of the troponin complex — it anchors the regulatory machinery to the thin filament and transmits the calcium signal into mechanical force into a conformation that lets the myosin motors fire. When calcium retreats, troponin T reverts, the motors disengage, and the heart relaxes. The TNNT2 R141W variant — an arginine-to-tryptophan substitution at codon 141 (or 151, depending on transcript isoform) — breaks this feedback loop by making the troponin T–tropomyosin complex abnormally stable. The motors do not disengage as completely; the heart struggles to generate force proportional to the available calcium signal. The result is dilated cardiomyopathy (DCM)²² dilated cardiomyopathy (DCM)
Dilated cardiomyopathy: the left ventricle enlarges and weakens, reducing pump efficiency. In genetic forms, onset often occurs in the second to fourth decade and can progress to heart failure, arrhythmia, or sudden death — and in some families, left ventricular noncompaction (LVNC).

The variant is classified Pathogenic/Likely pathogenic by ClinVar (VCV000012414) with 16 of 20 independent submitters in agreement and a two-star review status. OMIM lists it as allelic variant 191045.0007. It is absent from gnomAD population databases at meaningful frequency, consistent with a disease allele under strong negative selection.

The Mechanism

Arginine 141 sits within the tropomyosin-binding domain³³ tropomyosin-binding domain
The region of TNNT2 that physically contacts alpha-tropomyosin along the thin filament; mutations here alter how tightly the troponin complex holds tropomyosin in the "off" position of cardiac troponin T. The arginine residue is positively charged and normally forms a salt bridge with glutamic acid 257 of alpha-tropomyosin. Replacing it with tryptophan — a bulky, hydrophobic residue — destroys this salt bridge and instead locks tropomyosin into an over-stabilized interaction with troponin T; quartz-crystal microbalance experiments⁴⁴ quartz-crystal microbalance experiments
A technique that measures binding kinetics between purified proteins with nanogram sensitivity by detecting changes in oscillation frequency as mass accumulates on a crystal surface showed the R141W mutation increases troponin T affinity for alpha-tropomyosin approximately three-fold compared to wild-type.

The functional consequence is paradoxical: stronger troponin T–tropomyosin binding makes it harder to open the thin filament, not easier. Troponin I, the inhibitory subunit, retains the thin filament more effectively in the blocked state, requiring higher intracellular calcium concentrations to generate the same contractile force — a state called calcium desensitization⁵⁵ calcium desensitization
Reduced myofilament sensitivity to calcium: the heart must work harder to sustain output, which over time drives maladaptive remodeling — chamber dilation, fibrosis, and impaired systolic function.

The Evidence

Lu et al., 2003⁶⁶ Lu et al., 2003
Lu QW et al., J Mol Cell Cardiol 2003;35:1377–83 — in vitro reconstitution with recombinant human TNNT2 R141W and alpha-tropomyosin; quartz-crystal microbalance binding assays and skinned fiber mechanics in rabbit cardiac muscle provided the first molecular explanation for R141W's DCM mechanism: three-fold tighter tropomyosin binding and direct demonstration of reduced Ca²⁺ sensitivity of force development.

Ramratnam et al., 2016⁷⁷ Ramratnam et al., 2016
Ramratnam M et al., PLoS One 2016;11(12):e0167681 — gene-targeted knock-in mouse model (Tnnt2^R141W/+); optical mapping, echocardiography, skinned fiber mechanics, and β-adrenergic stress testing in heterozygous mice demonstrated that heterozygous mice develop overt DCM with left ventricular dilation, reduced contractility, and significant Ca²⁺ desensitization. Hearts compensated by raising peak systolic calcium transient amplitude by 54% above wild-type — but this compensation prolonged the diastolic calcium fall and impaired cardiac responses to stress. Male mice had significantly worse survival than females (P<0.001), suggesting sex-modifying factors.

Hershberger et al., 2009⁸⁸ Hershberger et al., 2009
Hershberger RE et al., Circ Cardiovasc Genet 2009;2(4):306–13 — bidirectional resequencing of TNNT2 in 313 DCM probands; functional testing in porcine cardiac fiber preparations found TNNT2 mutations in 2.9% of DCM probands, characterized by early-onset aggressive disease (median onset 32.5 years) with Ca²⁺ desensitization as the consistent functional hallmark. The R141W variant was found in 3 individuals with DCM and segregated with disease in 16 affected relatives from 2 families; it also occurred de novo in one individual with LVNC — the first documented de novo R141W case.

Klaassen et al., 2008⁹⁹ Klaassen et al., 2008
Klaassen S et al., Circulation 2008;117(22):2893–901 — systematic sequencing of MYH7, ACTC, and TNNT2 in 63 unrelated adult LVNC probands identified heterozygous sarcomeric mutations in 11 of 63 cases (17%), including one TNNT2 mutation, establishing that the same sarcomeric gene variants that cause HCM and DCM can also present as LVNC — a phenotypically distinct condition sharing overlapping genetic architecture.

An iPSC model of pediatric DCM from TNNT2 R151W confirmed the calcium desensitization and sarcomere disorganization in patient-derived cardiomyocytes, and showed that overexpression of wild-type TNNT2 partially rescued the contractile defect — early evidence supporting future gene-therapy approaches.

Practical Actions

The autosomal dominant nature of R141W means a single copy is sufficient to cause disease. Each first-degree relative of a carrier has a 50% chance of inheriting the variant. Penetrance is high but variable: in the original R141W family, 5 of 19 carriers were phenotypically unaffected at evaluation ages ranging from 1 to 47 years, indicating that age-dependent penetrance and environmental modifiers influence expression.

Cardiac management follows current DCM and LVNC guidelines: establish baseline left ventricular dimensions and function, monitor for arrhythmias (atrial fibrillation affects 25–30% of LVNC patients; ventricular arrhythmias drive sudden death risk), consider anticoagulation (thromboembolism risk in LVNC is 21–38% over a lifetime), and use guideline-directed heart failure therapy (ACE inhibitors/ARBs, beta-blockers, diuretics) once systolic dysfunction develops.

Interactions

The R141W mutation has been reported in combination with an MYPN (myopalladin) S1296T variant in a family with severe LVNC — the compound digenic combination appeared to produce a more penetrant noncompaction phenotype than either variant alone, with Tnnt2 R141W/+ mice (but not Mypn S1296T/+ mice) showing cardiac hypertrabeculation and noncompaction in the murine model.

Other sarcomeric gene mutations in MYH7 (rs104894664), TPM1 (rs104894502, rs104894503), MYBPC3 (rs36211723), and ACTC (rs193922385) can produce overlapping DCM/LVNC/HCM phenotypes. "Double positive" sarcomeric genotypes — two pathogenic variants in different sarcomeric genes — are associated with earlier onset and more severe disease.

Intracranial aneurysms — balloon-like dilations of cerebral arteries¹¹ balloon-like dilations of cerebral arteries
abnormal sac-like outpouchings that form at vessel bifurcations, most commonly in the circle of Willis — affect roughly 3% of the general population. Most remain silent throughout a person's lifetime, but rupture causes a sudden and devastating subarachnoid hemorrhage with mortality exceeding 40% and permanent disability in half of survivors. Identifying who carries elevated genetic susceptibility is a clinically meaningful step toward targeted surveillance.

The rs767603 variant sits on chromosome 14 at position 60,631,965 (GRCh38), within a genomic region mapped to the ANIB8 susceptibility locus (OMIM 612162). The locus is annotated near LOC105378189, a long non-coding RNA (lncRNA) gene of uncertain function. The variant has no protein-coding consequence — it sits in regulatory sequence, potentially influencing the expression of nearby genes involved in vascular wall maintenance.

The Mechanism

LOC105378189 is a computationally predicted lncRNA at chromosome 14q23. Long non-coding RNAs in vascular tissue have been shown to regulate vascular smooth muscle cell phenotype, endothelial function, and extracellular matrix remodeling²² regulate vascular smooth muscle cell phenotype, endothelial function, and extracellular matrix remodeling
roles reviewed for lncRNAs ANRIL, H19, and lincRNA-p21 in arterial wall biology. The precise mechanism by which rs767603 influences aneurysm susceptibility is not established. The variant is believed to act as a regulatory tag — altering the expression of one or more genes at the 14q23 locus that govern vascular wall integrity, elastin organization, or smooth muscle cell contractility.

Genome-wide association studies of intracranial aneurysm have consistently implicated loci related to endothelial function and extracellular matrix maintenance. The chromosome 14q23 region overlaps with regulatory elements identified in endothelial cells, consistent with the broader observation that intracranial aneurysm heritability is enriched in endothelial cell epigenetic marks³³ intracranial aneurysm heritability is enriched in endothelial cell epigenetic marks
Bakker et al. Nature Genetics 2020, heritability enrichment analysis pointing to endothelial cell open chromatin.

The Evidence

The primary evidence for rs767603 comes from a Japanese case-control study by Mineharu et al. 2008⁴⁴ Mineharu et al. 2008
Association analyses confirming a susceptibility locus for intracranial aneurysm at chromosome 14q23, J Hum Genet 53:325–332. Using GeneChip 10K array genotyping in 29 patients with intracranial aneurysm from a geographically clustered Japanese community (Akita) and 35 controls, the study identified rs767603 as the sole variant reaching Bonferroni-corrected significance. The association was confirmed by both allelic analysis (p=0.00017, Bonferroni p=0.021) and haplotype analysis (p=0.00178, Bonferroni p=0.048). Crucially, the finding replicated in an independent nationwide Japanese cohort of 237 aneurysm patients and 253 controls (allelic p=0.0046, haplotype p=0.0060).

Chromosome 14q23 was independently supported by linkage analysis in two large familial aneurysm kindreds showing a parametric LOD score of 3.0 between markers rs2359991 and rs2373098, flanking the rs767603 region⁵⁵ flanking the rs767603 region
molecular genetic analysis linking chromosome 14q23-31 to familial intracranial aneurysm in Dutch and Finnish pedigrees.

The evidence level is classified as moderate: the association is replicated within a Japanese population and supported by independent linkage data, but large-scale multi-ancestry GWAS have not singled out rs767603 as a lead SNP in European populations, and no functional annotation (eQTL, chromatin accessibility, protein interaction) has been reported for this variant.

Practical Actions

For individuals carrying the T allele — particularly TT homozygotes — the most clinically useful action is enhanced cardiovascular surveillance. Clinical guidelines recommend MRI angiography (MRA) screening for first-degree relatives of known aneurysm patients, especially those with a history of hypertension or smoking. Genetic susceptibility adds independent information that can inform the timing and frequency of surveillance.

Blood pressure control is the most modifiable environmental factor for aneurysm growth and rupture risk. Hypertension accelerates the hemodynamic stress on arterial walls that promotes aneurysm formation and enlargement. For T-allele carriers, maintaining tightly controlled blood pressure — ideally below 130/80 mmHg — is a genotype-informed priority.

Smoking is the strongest modifiable environmental risk factor for intracranial aneurysm formation and rupture, independent of genetics. Genetic susceptibility and smoking act synergistically — the combination of rs767603 T-allele status and active smoking substantially elevates absolute risk beyond either factor alone.

Interactions

The 14q23 susceptibility locus for intracranial aneurysm overlaps in pathway terms with other established aneurysm risk loci, including rs1333040 at 9p21 (a robustly replicated IA locus near CDKN2A/B), and loci on chromosomes 10q24, 13q13, and 2q33 identified in large-scale European GWAS. These variants likely act through convergent mechanisms — endothelial dysfunction, smooth muscle phenotype switching, and extracellular matrix remodeling — rather than direct gene-gene epistasis. No documented compound interaction between rs767603 and other aneurysm SNPs has been studied.

SOX17 is not a structural gene — it is a master regulator. SOX17¹¹ SOX17
SRY-related HMG-box 17: a transcription factor essential for specification and maintenance of endothelial cell identity during embryonic and adult vascular development encodes a transcription factor that directly controls the genetic programs that make endothelial cells — the cells lining every blood vessel in the body — what they are. When SOX17 expression is altered, the endothelial monolayer loses integrity, vessel walls weaken, and the hemodynamic stresses of arterial blood flow become harder to contain. rs9298506 is a regulatory tag variant located approximately 64 kilobases downstream of the SOX17 coding sequence at chromosome 8q11.23. It does not change the SOX17 protein directly, but by sitting in regulatory sequence it can influence how much SOX17 is produced — with consequences for vascular wall maintenance throughout life.

The Mechanism

SOX17 regulates endothelial cell fate from embryogenesis through adulthood. It targets genes that govern endothelial junction integrity, vascular smooth muscle cell communication, and extracellular matrix remodeling. Arterial branch points — particularly those in the cerebral circulation where intracranial aneurysms preferentially form — experience the highest hemodynamic shear stress in the body. SOX17 expression maintains the shear-stress response program²² SOX17 expression maintains the shear-stress response program
Loss-of-function experiments show that SOX17-depleted endothelial cells fail to upregulate junction proteins and are more prone to inflammatory activation under flow conditions. When this transcriptional program is subtly impaired by a regulatory variant, the cumulative effect over decades may be a vessel wall that is marginally less resistant to aneurysm formation.

The GWAS Catalog annotates rs9298506 near the RP1 gene (8q12.1), but the 2008 Bilguvar discovery team explicitly noted that associated SNPs on 8q "likely act via SOX17, which is required for formation and maintenance of endothelial cells, suggesting a role in development and repair of the vasculature." The variant's position and the biological plausibility of SOX17 as the effector gene make this the most mechanistically coherent explanation. Heritability enrichment analysis³³ Heritability enrichment analysis
identifying which cell types' open chromatin regions explain the most GWAS signal from the 2020 Bakker et al. GWAS independently confirmed that intracranial aneurysm heritability is concentrated in endothelial cell epigenetic marks — exactly the cell type SOX17 controls.

The Evidence

The original discovery came from the landmark Bilguvar et al. 2008⁴⁴ Bilguvar et al. 2008
Susceptibility loci for intracranial aneurysm in European and Japanese populations, Nature Genetics genome-wide association study. Spanning Finnish, Dutch, and Japanese cohorts totalling more than 2,100 intracranial aneurysm cases and 8,000 controls, the study identified the chromosome 8q locus — with rs9298506-A as the risk allele — among three genome-wide significant hits (OR approximately 1.35 in the 8q range).

The 8q SOX17 association was confirmed in a larger Yasuno et al. 2010⁵⁵ Yasuno et al. 2010
Genome-wide association study of intracranial aneurysm identifies three new risk loci, Nature Genetics multi-cohort GWAS: 5,891 cases and 14,181 controls from European and Japanese populations. rs9298506-A reached p=1×10⁻¹² with OR 1.28 (95% CI 1.20–1.38) — each copy of the A allele raises intracranial aneurysm odds by approximately 28% relative to the protective G allele.

A Korean case-control and East-Asian meta-analysis⁶⁶ Korean case-control and East-Asian meta-analysis
Hong et al. 2018 World Neurosurgery pooling 5,100 IA cases and 7,930 controls confirmed the rs9298506 association in Asian populations: OR 1.19 (95% CI 1.07–1.32, p=0.0016) for the A allele risk direction, consistent across ancestry groups. The Bakker et al. 2020⁷⁷ Bakker et al. 2020
Nature Genetics cross-ancestry GWAS of 10,754 cases and 306,882 controls further validated that loci in this region contribute to intracranial aneurysm risk within a polygenic architecture, with heritability concentrated in endothelial cell biology.

A Deka et al. 2010⁸⁸ Deka et al. 2010
Stroke study of 406 familial IA cases found that the 8q11 SOX17 signal (rs10958409, in strong LD with rs9298506) interacted multiplicatively with smoking — a gene-environment interaction meaning the risk conferred by this locus is significantly amplified in smokers. This is one of the strongest gene-environment interactions documented for intracranial aneurysm risk.

The evidence is classified as strong: consistent replication across European and East Asian GWAS in independent cohorts, a clear biological candidate gene with an established vascular role, and documented gene-environment interaction with smoking.

Practical Actions

The A allele at rs9298506 is the most common allele globally (~81%), meaning the majority of people carry at least one copy. However, the per-allele OR of ~1.28 is real and clinically meaningful — it is comparable in magnitude to other established cardiovascular risk variants. For AA homozygotes, the cumulative effect of two risk alleles is particularly relevant when combined with other risk factors.

The two most important actionable modifiers of SOX17-locus aneurysm risk are: smoking cessation (the gene-environment interaction documented by Deka et al. means smoking specifically amplifies 8q11 locus risk) and blood pressure control (the primary hemodynamic driver of aneurysm formation and rupture regardless of genetic background). For individuals with a family history of intracranial aneurysm or subarachnoid hemorrhage, this genetic finding adds weight to the case for discussing proactive MRI angiography screening with a physician.

Interactions

rs9298506 is the second SOX17-region variant in this intracranial aneurysm panel; the other SOX17-region GWAS tag SNP rs10958409 (analyzed in the Deka 2010 Stroke study) is in linkage disequilibrium with rs9298506 and tags the same 8q11.23 susceptibility locus. These two SNPs should not be treated as additive independent risk signals — they reflect the same underlying association.

The SOX17 locus acts additively with other independently replicated intracranial aneurysm susceptibility loci, including rs1333040 at 9p21 (near CDKN2A/B, the most robustly replicated IA locus), rs700651 at 2q33.1 (BOLL), and rs767603 at 14q23. These loci operate through distinct pathway nodes — endothelial identity (SOX17), cell cycle senescence (9p21), RNA splicing regulation (2q33.1), and vascular wall regulatory elements (14q23) — and their risk contributions are additive in polygenic models. Individuals carrying risk alleles across multiple loci have substantially higher absolute risk than any single locus implies.

Your brain's response to stress depends on a continuous supply of new neurons in the hippocampus — a process called adult hippocampal neurogenesis. This region serves double duty: it encodes memory and, critically, it provides inhibitory control over the HPA axis¹¹ HPA axis
The hypothalamic-pituitary-adrenal axis: the hormonal cascade where the hypothalamus signals the pituitary, which signals the adrenal glands to release cortisol. Healthy hippocampal neurogenesis helps shut this response off. The gene STK24 — encoding a kinase called MST3 — turns out to be essential for keeping that factory running. Variants near STK24, including rs9556979, may influence how well the hippocampus maintains its stress-dampening capacity.

STK24 belongs to the germinal center kinase-III (GCK-III) subfamily of Ste20-related kinases. Unlike most brain-relevant genes that encode neurotransmitter receptors or ion channels, STK24 encodes a master regulator of brain architecture itself — controlling how neurons move into position, grow their dendrites, and form synapses during development and throughout life.

The Mechanism

The rs9556979 variant sits approximately 12 kilobases downstream of the STK24 gene, in a region classified as regulatory. Variants in this position can alter promoter activity, enhancer function, or transcription factor binding that fine-tunes STK24 expression in neural tissue.

Inside neurons, STK24/MST3 operates through at least two critical pathways. First, it regulates neuronal migration²² neuronal migration
The developmental process by which newly born neurons travel from their birthplace in the ventricular zone to their final position in the cortical layers. Correct positioning is essential for functional circuit formation. Tang et al. 2014³³ Tang et al. 2014
Tang J et al. Cdk5-dependent Mst3 phosphorylation and activity regulate neuronal migration through RhoA inhibition. J Neurosci, 2014 showed that MST3 is activated by Cdk5 phosphorylation at Ser79, then phosphorylates RhoA at Ser26 to suppress its GTPase activity — releasing the cytoskeletal brake that allows neurons to extend a leading process and migrate. Silencing Mst3 in developing mouse cortex trapped neurons in a disorganized multipolar state, unable to complete their journey.

Second, in mature neurons, MST3 promotes dendritic spine and synapse formation. Ultanir et al. 2014⁴⁴ Ultanir et al. 2014
Ultanir SK et al. MST3 kinase phosphorylates TAO1/2 to enable Myosin Va function in promoting spine synapse development. Neuron, 2014 found that MST3 phosphorylates TAO1/2 kinases, which direct the motor protein Myosin Va to dendritic spines. Depleting MST3 reduced spine density in hippocampal cultures and in intact layer 2/3 pyramidal neurons.

The 2025 animal model study provides the clearest link to mood and stress. Wu et al. 2025⁵⁵ Wu et al. 2025
Wu KY et al. Stk24 deficiency causes disrupted hippocampal neurogenesis and anxiety-like behavior in mice. Commun Biol, 2025 generated brain-specific Stk24 conditional knockout mice and found that deleting the gene reduced the number of TBR2+, NeuroD+, and DCX+ cells (markers of newborn neurons at successive stages of maturation) and NeuN+/BrdU+ co-labeled mature new neurons in the dentate gyrus. Under stress, these mice had significantly higher plasma corticosterone and greater c-FOS+ neuronal activation than wild-type controls, with upregulated CRH expression — a signature of impaired hippocampal inhibition of the HPA axis. Behaviorally, knockout mice spent more time in exposed areas (center of open field, light compartment of light-dark box), consistent with anxiety-like disinhibition.

The Evidence

Human genetic evidence for STK24's role in anxiety comes from two sources. A genome-wide study of psycho-emotional well-being in 30,063 Russians⁶⁶ 30,063 Russians
Yakovchik AY et al. Genetics of psycho-emotional well-being: genome-wide association study and polygenic risk score analysis. Front Psychiatry, 2024 identified rs9517326 — a neighboring STK24 variant — as significantly associated with HADS-A anxiety scores alongside PTPRN2 and DLGAP4, genes involved in excitatory neurotransmission. The study highlighted STK24's role in neurogenesis and synaptic function as the mechanistic basis.

At the population scale, the largest anxiety GWAS to date — Strom, Levey et al. 2024⁷⁷ Strom, Levey et al. 2024
Strom NI, Levey DF et al. Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling. medRxiv, 2024 — identified 58 loci for major anxiety disorders and underscored the role of genes affecting synaptic biology and neurogenesis. GWAS catalog data show rs9556979 is also associated with body shape measurements (p=3×10⁻¹⁰) and metabolic syndrome (p=1×10⁻¹⁴) — consistent with STK24's broader roles in stress physiology and the brain-metabolic axis.

Practical Implications

The evidence positions STK24 rs9556979 as a moderator of hippocampal resilience under stress. G allele carriers may have reduced STK24 expression in neural tissue, leading to modestly impaired adult hippocampal neurogenesis and a slightly less efficient brake on the HPA stress axis. The practical consequence is a stress response that tends to run somewhat longer and stronger — not a psychiatric diagnosis, but a biological predisposition worth knowing.

Interventions that directly stimulate hippocampal neurogenesis are relevant here: aerobic exercise is the most robustly validated, increasing BDNF and new neuron production within 4-6 weeks of consistent training. Dietary approaches that support BDNF (adequate omega-3 EPA/DHA, sufficient zinc and magnesium) and reduce neuroinflammation may also support hippocampal neurogenesis capacity.

Interactions

rs9556979 and FKBP5 rs1360780 operate through overlapping HPA axis pathways — STK24 affecting the neurogenic brake on cortisol release, and FKBP5 affecting the glucocorticoid receptor feedback loop. Carriers of risk alleles at both loci would be expected to show additive impairment in stress resolution.

BDNF rs6265 (Val66Met) is also relevant: since STK24 supports the structural substrate for hippocampal neurogenesis and BDNF provides the survival signal for new neurons, carriers of both the G allele at rs9556979 and the Met allele at rs6265 may have compounded reduction in adult neurogenesis capacity.

TFAP2B (Transcription Factor AP-2 Beta) encodes a transcription factor expressed preferentially in adipose tissue¹¹ adipose tissue
Fat tissue, where this gene regulates the development and function of fat-storing cells. Unlike variants that affect how much you eat (appetite genes), TFAP2B influences how your body distributes and stores fat — particularly around the waist. The rs987237 variant was among the first three loci identified for central adiposity in large-scale genome-wide association studies.

The Mechanism

TFAP2B regulates adipocyte differentiation and adipokine expression²² adipokine expression
Signaling molecules secreted by fat cells, including leptin (satiety signal) and adiponectin (insulin sensitivity regulator). The G allele at rs987237 sits within an intronic regulatory region that alters TFAP2B expression in adipose tissue. Carriers of the G allele show lower circulating leptin levels³³ lower circulating leptin levels
Leptin tells the brain about fat stores; lower levels may impair satiety signaling (approximately 2.7 ng/ml reduction), suggesting functional consequences for how fat cells communicate with the rest of the body.

The Evidence

The landmark GWAS meta-analysis⁴⁴ landmark GWAS meta-analysis
Lindgren et al. Genome-wide association scan meta-analysis identifies three loci influencing adiposity and fat distribution. PLoS Genet, 2009 identified rs987237 as genome-wide significant for waist circumference (P = 1.9 x 10^-11) in a meta-analysis of 16 GWAS studies comprising 38,580 individuals with replication in up to 70,689 additional subjects.

The most striking finding involves gene-diet interaction. In a clinical trial of 771 participants⁵⁵ clinical trial of 771 participants
Stocks et al. TFAP2B influences the effect of dietary fat on weight loss under energy restriction. PLoS ONE, 2012, TFAP2B rs987237 modified the effect of dietary fat on weight loss with a P-value for interaction of 0.00007. AA homozygotes lost 1.0 kg more on low-fat diets, while GG homozygotes lost 2.6 kg more on high-fat diets. This suggests opposite optimal dietary strategies depending on genotype.

A follow-up in the DiOGenes trial⁶⁶ DiOGenes trial
Stocks et al. TFAP2B-dietary protein and glycemic index interactions and weight maintenance after weight loss in the DiOGenes trial. Hum Hered, 2013 found that TFAP2B also interacts with dietary protein content during weight maintenance, though the pattern differed from the weight-loss phase — suggesting context-dependent gene-diet interactions.

In a study of 13,507 adult Danes⁷⁷ study of 13,507 adult Danes
Bille et al. Implications of central obesity-related variants in LYPLAL1, NRXN3, MSRA, and TFAP2B on quantitative metabolic traits in adult Danes. PLoS ONE, 2011, the variant showed nominal associations with central obesity measures and was associated with reduced leptin levels.

Practical Actions

If you carry the G allele, you may respond differently to dietary fat levels during weight management. While GG homozygotes paradoxically appear to lose more weight on higher-fat diets, this genotype is also associated with greater central fat distribution. Monitoring your waist circumference and waist-to-hip ratio provides more meaningful feedback than weight alone.

Interactions

TFAP2B sits in the same biological context as other central adiposity loci. Carriers of risk alleles at both rs987237 (TFAP2B) and rs7903146 (TCF7L2) face compounded effects on fat distribution and metabolic risk, since both genes influence adipocyte function through different pathways — TFAP2B via adipokine regulation and TCF7L2 via Wnt signaling in pancreatic beta cells.

Atopic dermatitis affects up to 20% of children and persists into adulthood in roughly a third of cases. What determines whether a child's eczema resolves within a few years or becomes a lifelong burden? Part of the answer lies in a single intronic variant in the TSLP gene on chromosome 5. The rs1898671 T allele is consistently associated with milder, shorter-lived atopic dermatitis — a genetic factor that predicts disease trajectory well before a child sees their first dermatologist.

TSLP (thymic stromal lymphopoietin) is a cytokine¹¹ cytokine
A small signaling protein secreted by immune and epithelial cells to coordinate inflammatory responses produced primarily by keratinocytes in the skin barrier. When the skin is breached — by allergens, irritants, or filaggrin loss-of-function mutations — keratinocytes release TSLP as an alarmin²² alarmin
An "alarm signal" molecule released by stressed or damaged cells to activate innate and adaptive immunity that instructs dendritic cells and innate lymphoid cells to drive a Th2-skewed inflammatory response. This cascade — TSLP → dendritic cell activation → Th2 polarization → IL-4/IL-13/IL-31 production — is the central pathway in atopic dermatitis pathogenesis. Genetic variation at rs1898671 appears to modulate baseline TSLP output or activity, setting the gain on this entire signaling chain.

The Mechanism

rs1898671 is located within intron 1 of TSLP on chromosome 5q22.1 (GRCh38 position 111,072,304), approximately 2 kb from the transcription start site. It does not change any amino acid in the TSLP protein; instead, it likely affects intronic regulatory elements³³ intronic regulatory elements
Introns contain enhancers, silencers, and splice-site sequences that modulate how much mRNA is produced from a gene that control TSLP expression levels or alternative isoform splicing. TSLP exists as two isoforms: a short form with antimicrobial properties and a long form that drives type 2 allergic inflammation. The intronic position of rs1898671 is consistent with a role in regulating this isoform balance or baseline transcription rate.

The net result: T allele carriers appear to produce or signal through less inflammatory-isoform TSLP under basal conditions. When the skin barrier is intact, this difference may be negligible. But when a barrier defect (such as a filaggrin mutation) floods the skin with allergen exposure, lower TSLP output fundamentally changes the amplitude of the resulting Th2 response — which is precisely what the gene-gene interaction data shows.

The Evidence

The clearest evidence comes from the Pediatric Eczema Elective Registry⁴⁴ Pediatric Eczema Elective Registry
A multicenter longitudinal registry of children with atopic dermatitis followed from early childhood into adolescence (PEER), where 796 children were followed prospectively. Among white children, the T allele at rs1898671 was significantly associated with less persistent atopic dermatitis (OR 1.72; 95% CI 1.11–2.66; P = .01). In children who also carried filaggrin (FLG) loss-of-function mutations — the strongest known genetic risk factor for AD — the TSLP T allele dramatically amplified the disease-moderating effect (OR 4.92; 95% CI 2.04–11.86). This gene-gene interaction makes mechanistic sense: FLG mutations create the skin breach that maximizes TSLP release; the rs1898671 T allele then limits how loudly the alarm sounds.

A 7.6-year follow-up study⁵⁵ 7.6-year follow-up study
842 children, ~6,396 person-years of observation of the same registry found that TT homozygotes for rs1898671 were substantially less likely to require topical calcineurin inhibitors — a second-line immunosuppressive class — for disease control (OR 0.16; 95% CI 0.06–0.42). When children did discontinue calcineurin inhibitors, T allele carriers were more likely to stop all treatments entirely (OR 0.45; 95% CI 0.26–0.76), consistent with genuine disease remission rather than treatment switching.

A fine-mapping study⁶⁶ fine-mapping study
A genetic technique that sequences all variants in a region at high resolution to identify which specific SNP drives the association signal, rather than which SNP happens to be genotyped on a chip using targeted massively parallel sequencing in two independent cohorts (741 + 585 children) confirmed the T allele's protective effect: white children with the variant were less likely to develop AD at all (OR 1.41; 95% CI 1.20–1.66), with heterozygotes showing stronger protection (OR 1.91) than homozygotes (OR 1.28) — a non-linear pattern that suggests haploinsufficiency or threshold effects in the TSLP signaling chain.

One important caveat: rs1898671 has divergent effects across atopic conditions. A meta-analysis of 6,351 rhinitis cases⁷⁷ meta-analysis of 6,351 rhinitis cases and 11,472 controls found the T allele associated with modestly increased allergic rhinitis risk (OR 1.13; 95% CI 1.07–1.20). This opposing direction is not contradictory — it likely reflects the different inflammatory contexts of upper airway vs. skin-barrier pathology and the TSLP isoform balance in different tissue compartments. For GeneOps users, this means the T allele's favorable effect on AD persistence does not imply lower risk of all atopic conditions.

Practical Implications

T allele carriers with atopic dermatitis can take some reassurance that their genetics favor a milder disease course and higher probability of remission. TT homozygotes in particular are markedly less likely to require systemic or intensive topical immunosuppression over time. This does not eliminate the need for standard AD management — emollients, barrier repair, and trigger avoidance remain essential regardless of genotype — but it informs expectations about long-term trajectory.

For CC homozygotes (no T allele), the data suggest higher TSLP activity and a greater probability of persistent, treatment-requiring disease. Proactive barrier maintenance and early dermatologist involvement at first signs of significant flares may matter more for this group. Additionally, if they also carry FLG loss-of-function mutations (testable separately), the combination identifies the highest-risk AD subgroup. Anti-TSLP biologics (tezepelumab, in trials for AD) are a treatment avenue particularly relevant for high-TSLP individuals who fail standard therapy.

Interactions

The interaction between rs1898671 and filaggrin (FLG) loss-of-function mutations is the most clinically documented at this locus. In individuals with both a FLG null allele and the TSLP rs1898671 T variant, disease persistence was markedly reduced compared to those carrying FLG mutations without the T allele (OR 4.92). This suggests the two genes operate in sequence: FLG determines how much allergen penetrates; TSLP determines how loudly the alarm sounds in response. Reducing either signal attenuates the cascade.

The 5q22.1 locus (TSLP neighborhood) also harbors rs1837253 in TSLP's upstream region, a variant more strongly associated with asthma and eosinophilic esophagitis; rs1898671 and rs1837253 tag partially overlapping but distinct TSLP regulatory signals.

TSLP is upstream of the IL-4Rα signaling axis targeted by dupilumab. In AD patients who fail to respond adequately to dupilumab, elevated TSLP-driven IL-33 and TSLP-independent ILC2 activation may partially explain residual disease — making TSLP genotype relevant to treatment selection discussions.

Before your body can absorb folate from food, it has to be broken down first. Dietary folate arrives primarily as polyglutamated folate¹¹ polyglutamated folate
Folate from food (spinach, lentils, liver) is attached to a chain of glutamate molecules — up to 8 in some foods. This polyglutamate form cannot cross the intestinal wall. — folate molecules with long glutamate tails that cannot cross the intestinal wall intact. FOLH1 (also called GCPII, glutamate carboxypeptidase II) is the enzyme anchored to the intestinal brush border that clips those tails one by one, releasing the absorbable monoglutamate form. Without adequate GCPII activity, a meaningful fraction of the folate in your food passes through unabsorbed.

rs202720 is an intronic variant in FOLH1 located at chromosome 11, position 49,170,799. It does not change the amino acid sequence of the GCPII enzyme, but intronic variants can influence gene expression, mRNA splicing efficiency, or transcript stability. The C allele is common globally — carried by roughly one in three people — with notable variation across ancestries.

The Mechanism

The GCPII enzyme is a type II transmembrane metallopeptidase expressed on the apical surface of jejunal enterocytes²² jejunal enterocytes
Enterocytes are the absorptive cells lining the small intestine, particularly the jejunum, where folate absorption occurs.. It processes dietary polyglutamated folates into the monoglutamate form that the proton-coupled folate transporter (PCFT/SLC46A1)³³ proton-coupled folate transporter (PCFT/SLC46A1)
PCFT is the main folate uptake transporter at the intestinal brush border and in the choroid plexus. Mutations causing it to fail result in hereditary folate malabsorption. can then actively transport across the gut wall.

rs202720 lies approximately 396 nucleotides into an intron of FOLH1 and affects at least six annotated transcripts. Because it is intronic with no coding consequence, the functional mechanism is indirect — likely a regulatory effect on FOLH1 expression levels or alternative splicing of FOLH1 isoforms. The well-studied missense variant in FOLH1, His475Tyr ⁴⁴ H475Y (rs61886492) is the most functionally characterized FOLH1 variant: it reduces intestinal GCPII enzyme activity by approximately 53% (Devlin et al. 2000, PMID 11092759)., provides a molecular model for how reduced GCPII activity translates into lower dietary folate bioavailability.

The Evidence

Direct evidence for rs202720 specifically is limited. The variant has been genotyped in an elderly Brazilian cohort⁵⁵ elderly Brazilian cohort
Mazzotti DR et al. Association of APOE, GCPII and MMP9 polymorphisms with common diseases and lipid levels. Gene, 2014 (C allele frequency 26.6%) without significant disease or lipid associations reported for this specific variant. A pathway-wide association study⁶⁶ pathway-wide association study
Boyles AL et al. Oral facial clefts and gene polymorphisms in metabolism of folate. Genet Epidemiol, 2009 of 425 case-parent triads found FOLH1 variants showed the strongest gene-level signal for cleft palate only (P=0.0008), though causality and which specific FOLH1 SNP drove the signal were not established.

The broader FOLH1/GCPII biology is well established. The functionally characterized H475Y missense variant (rs61886492) reduces GCPII enzyme activity by 53% in cellular models⁷⁷ 53% in cellular models
Devlin AM et al. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet, 2000 and is associated with lower serum folate and higher homocysteine in population studies. A Dutch study of 791 adults found that GCPII 1561T allele carriers had significantly higher red blood cell and plasma folate⁸⁸ significantly higher red blood cell and plasma folate
Lievers KJA et al. Influence of GCPII polymorphism on plasma homocysteine, folate and vitamin B12 levels. Atherosclerosis, 2002 and lower homocysteine, suggesting the variant alters folate status beyond its direct effect on polyglutamyl cleavage — pointing to regulatory mechanisms, possibly involving expression-level differences of the type that an intronic variant like rs202720 could produce.

A controlled bioavailability study found that polyglutamyl folic acid bioavailability did not differ⁹⁹ polyglutamyl folic acid bioavailability did not differ
Melse-Boonstra A et al. Bioavailability of polyglutamyl folic acid relative to monoglutamyl folic acid. Am J Clin Nutr, 2004 significantly between GCPII genotypes (64% vs. 70%), suggesting the observed differences in folate status likely arise from changes in GCPII expression rather than altered enzyme kinetics. This mechanistic pathway — intronic variant → altered expression → changed folate absorption efficiency — is consistent with the functional category of rs202720.

Practical Actions

Given the emerging and indirect nature of the evidence, strong clinical recommendations specific to rs202720 cannot be made with confidence. However, individuals with the CC genotype who have low dietary folate intake may have reduced GCPII expression and consequently lower folate bioavailability from food sources. Supplementing with monoglutamyl forms of folate (folic acid or 5-methyltetrahydrofolate/5-MTHF) bypasses GCPII entirely: these forms do not require enzymatic deconjugation before absorption. Measuring serum folate or red blood cell folate can confirm whether absorption is adequate.

Interactions

rs202720 belongs to the broader intestinal folate absorption step, upstream of the methylation cycle. A CC genotype here compounds with any downstream methylation variant — particularly MTHFR C677T (rs1801133) and A1298C (rs1801131) — since less folate entering the cycle means less substrate for an already-impaired MTHFR enzyme. rs1051266, the SLC19A1 G80A variant controlling folate transport into cells, represents the next step in the pathway after GCPII absorption. The well-characterized FOLH1 missense variant rs61886492 (H475Y) is the primary functional variant in this gene; the relationship between rs202720 and rs61886492 in terms of linkage disequilibrium has not been formally published, making it uncertain whether they tag the same functional haplotype.

Your brain maintains a precise balance between neuronal excitation and inhibition. When that balance shifts toward excess excitation — particularly in the cortex — it can trigger cortical spreading depression¹¹ cortical spreading depression
a slow wave of neuronal depolarisation that propagates across the cortex and is thought to underlie migraine aura and activate the trigeminal pain system. The gene MEF2D sits at a critical control point in this system: it is a transcription factor that governs how many excitatory synapses neurons maintain and how quickly they eliminate redundant connections.

The intronic variant rs2274319 is one of the most robustly replicated migraine risk variants in human genetics. The C allele, carried by roughly 64% of people globally, is associated with increased migraine susceptibility in the largest migraine GWAS ever conducted — 102,084 cases and 771,257 controls. The effect size is modest (OR=1.075 per C allele) but the statistical signal is overwhelming (P=3.0×10⁻⁴¹), placing the MEF2D locus among the most robustly confirmed migraine genes identified to date.

The Mechanism

MEF2D (myocyte enhancer factor 2D) is a calcium-activated transcription factor that is selectively expressed in post-mitotic neurons, where it regulates two fundamental processes: neuronal survival during development²² neuronal survival during development
MEF2D activates anti-apoptotic gene programs when calcium signals indicate a neuron has made appropriate synaptic connections, and excitatory synapse pruning in mature neurons.

The synapse regulation function is particularly relevant to migraine. MEF2 factors act as brakes on excitatory synapse number³³ brakes on excitatory synapse number
in an activity-dependent manner, MEF2 restricts how many AMPA-receptor-bearing synapses a neuron maintains, preventing runaway excitatory connectivity. When MEF2D is less active, neurons retain more excitatory synapses than they would otherwise. In hippocampal CA1 neurons, MEF2A/D specifically controls synapse silencing during brief burst firing⁴⁴ synapse silencing during brief burst firing
brief 1-hour periods of postsynaptic bursting selectively depress AMPA receptor transmission in a MEF2A/D-dependent manner, the first stage of synapse elimination. Loss of this function leaves excitatory circuits less able to self-regulate after periods of high activity.

The rs2274319 variant lies within an intron of MEF2D and is thought to affect regulatory elements governing MEF2D expression levels — not the protein sequence itself. The effect is gene-dosage: each C allele is associated with a small but measurable shift in migraine susceptibility, consistent with modest changes in MEF2D transcriptional activity in neurons that matter for migraine — cortical neurons and trigeminal ganglion neurons, where MEF2D is expressed and where excitability thresholds determine migraine vulnerability.

The Evidence

The primary evidence comes from Hautakangas et al. 2022⁵⁵ Hautakangas et al. 2022
Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nature Genetics, a landmark meta-GWAS that found rs2274319 at the MEF2D locus to be one of the top variants by effect size across all 123 identified loci (OR=1.075, P=3.0×10⁻⁴¹). This places MEF2D in the same tier as CALCA/CALCB (the gene encoding CGRP, the target of all currently approved migraine preventive biologics) and TRPM8 in terms of statistical reliability.

The MEF2D locus was first identified by the Freilinger et al. 2012⁶⁶ Freilinger et al. 2012
International Headache Genetics Consortium GWAS of migraine without aura. Nature Genetics consortium (combined P=7.06×10⁻¹¹ at the lead SNP rs3790455), and has been replicated in Chinese cohorts by An et al. 2017⁷⁷ An et al. 2017
Clinical Genetics (n=1,114; MEF2D variants significantly differentiated migraine cases from controls, especially for migraine without aura). The cross-ancestry replication strengthens confidence that the MEF2D association reflects a true biological effect rather than a population-specific artefact.

The mechanistic basis is supported by three independent experimental studies. Akhtar et al. 2012⁸⁸ Akhtar et al. 2012
PLoS One demonstrated using conditional knockout mice that MEF2A/D double deficiency produces impaired motor coordination and altered synaptic transmission, while triple MEF2A/C/D knockout causes frank neuronal apoptosis — showing that MEF2D is required for both synaptic homeostasis and neuronal survival. Chang et al. 2017⁹⁹ Chang et al. 2017
eLife pinpointed MEF2A/D as specifically required for activity-dependent AMPA receptor depression during burst firing in hippocampal neurons. Andzelm et al. 2019¹⁰¹⁰ Andzelm et al. 2019
Cell Reports showed that MEF2D (not MEF2A) is the specific isoform required for long-term synaptic depression in cerebellar Purkinje cells, and that MEF2 family members generally restrict excitatory synapse number during development.

Practical Actions

For C allele carriers (CT or CC genotype), the elevated migraine risk from the MEF2D locus is not modifiable in the sense that you cannot change your genotype. However, knowing you carry an increased baseline susceptibility does have practical implications: it informs how aggressively to pursue acute treatment, whether to consider preventive therapy, and which triggers to track carefully.

The MEF2D biology points toward excitability management as the core principle. Magnesium plays a specific role here — it is an NMDA receptor channel blocker and the only supplement with established clinical evidence for migraine prevention in randomised trials, mechanistically aligned with reducing excitatory synapse transmission. Riboflavin (vitamin B2) supports mitochondrial function in neurons and has RCT evidence for migraine prevention as well.

Interactions

rs2274319 is one of several genetic factors influencing migraine susceptibility in the neurology-cognition category. rs10166942 (TRPM8) encodes the cold-sensing ion channel that mediates the "ice cream headache" phenomenon and shows sex-specific migraine associations. rs1835740 near MTDH/PGCP affects glutamate homeostasis via the glial transporter pathway, a converging mechanism — excess synaptic glutamate and reduced MEF2D-mediated synapse elimination both shift cortical networks toward hyperexcitability. The combination of MEF2D CC genotype with other cortical excitability variants is worth noting to a neurologist when discussing preventive migraine therapy.